Objective: We previously reported that in the absence of hormone therapy (HT) or calcium/vitamin D (Ca/D) supplementation, earlier menopause age was associated with decreased bone mineral density and increased fracture risk in healthy postmenopausal women. Treatment with HT and Ca/D is protective against fractures after menopause. In this analysis, we asked if the age of menopause onset alters fracture risk in healthy postmenopausal women receiving HT, Ca/D, or a combination. Conclusions: In the overall Women's Health Initiative Clinical Trial cohort and within each treatment group, women with younger menopause age (<40 y) had a higher risk of any fracture than women reporting older menopause ages. The effect of menopause age on fracture risk was not altered by any of the treatment interventions (HT, Ca/D, HT þ Ca/D), suggesting that early age of menopause is an independent contributor to postmenopausal fracture risk.
O steoporotic fractures are a significant cause of morbidity and mortality in postmenopausal women. [1] [2] [3] [4] [5] [6] [7] The Women's Health Initiative Clinical Trial (WHI CT) was composed of three prospective, randomized, controlled trials investigating the effects of (1) hormone therapy (HT), (2) calcium and vitamin D (Ca/D) supplementation, and (3) a low fat, high fruit/vegetable/grain diet on morbidity and mortality in postmenopausal women. Eligible women were able to participate in one, two, or all three trials. Among the WHI CTs, primary outcome measures were the occurrence of osteoporotic fractures and modification of fracture rate by intervention with HT, Ca/D supplementation, or both (HT þ Ca/D). Results from the WHI CT showed that HT reduced the risk for osteoporotic fractures compared with placebo. [8] [9] [10] Ca/D treatment alone significantly decreased risk for hip fracture in women aged 60 or older, suggesting a longer duration of menopause may be associated with greater efficacy of treatment. 8 On the contrary, all participants treated with HT experienced a decrease in fracture rate compared with women taking placebo, and this effect was independent of participants' age or baseline risk for fracture. 9, 10 We recently reported that age of nonsurgical menopause onset is a risk factor for fracture among healthy postmenopausal women in the WHI Observational Study (WHI OS), in which there was no treatment intervention. 11 In the absence of HT or Ca/D supplementation, and after adjusting for known risk factors for fracture, women in the WHI OS who experienced early menopause (<40 y) had higher fracture rates than women who experienced menopause 12 At study enrollment, the following information was collected from all participants using standardized questionnaires: demographic information; complete personal medical history including medication history and current medication use, smoking status, alcohol consumption, and physical activity level (quantified in metabolic equivalents/wk based on the number of weekly sessions of recreational physical activity); and family history. Participants were instructed to bring all of their medications, including over-the-counter medications and dietary supplements, to the clinic for data recording. Current or prior use of HT was carefully documented. At baseline, information was collected regarding risk for fractures (such as personal history of fractures and personal history of an osteoporosis diagnosis) using standardized questionnaires. This included an assessment of total daily Ca/D intake from dietary sources and supplements. Physical and clinical measurements, performed by a certified WHI staff member, were collected at study entry using standardized protocols to assess height, weight, and blood pressure.
Fracture occurrences were collected from all responding WHI participants annually using standardized questionnaires. Fractures on which our analyses were based were only those that occurred after study enrollment. Fractures were categorized by site: hip/pelvis/upper leg, lower leg/ankle/knee, foot, upper arm/shoulder/elbow, lower arm/wrist/hand, and spine/ tailbone. Hip fractures were adjudicated using medical record data by centrally trained WHI physician adjudicators. Fracture events were adjudicated during the main WHI study (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) and through the end of the first WHI Extension Study (2005) (2006) (2007) (2008) (2009) (2010) .
All women in the Ca/D trial (n ¼ 36,282) were randomized using a permuted-block algorithm (stratified by study site and age) to receive either two tablets containing 500 mg of elemental calcium plus 200 IU of vitamin D daily (total daily dose 1,000 mg calcium and 400 IU vitamin D), or placebo pills daily. Women were allowed to enroll in the study if they took personal supplements of calcium and/or vitamin D at doses of not more than 1,000 mg calcium and 600 IU vitamin D daily. Among women in the Ca/D trial, 40% (n ¼ 14,507) self-reported use of both calcium and vitamin D, 11% (n ¼ 3,809) reported use of calcium only, 4% (n ¼ 1,272) reported use of vitamin D only, and 46% (n ¼ 16,693) reported no supplement use. The HT trial consisted of two possible interventions: (1) estrogen alone (E) and (2) estrogen þ progestin (EþP). Women who had undergone hysterectomy were eligible for the E 2 trial (n ¼ 10,739), whereas women with an intact uterus were eligible for the EþP trial (n ¼ 16,608). Among the women in the EþP trial, participants were randomly assigned to receive 0.625 mg/d of conjugated equine estrogens in combination with 2.5 mg/d of medroxyprogesterone acetate in a single pill (Prempro; Wyeth, Philadelphia, PA) (n ¼ 8,506) or matching placebo (n ¼ 8,102). All HT trial participants who were using HT at the time of enrollment were required to undergo a 3-month washout period before study initiation.
For this analysis, we included only women with an intact uterus to avoid confounding data with women who had undergone surgical menopause and for whom natural menopause age was consequently not able to be determined. Thus, we included only women in the EþP arms of the HT and HT þ Ca/D trials. Self-reported age of menopause was grouped as follows: menopause <40, 40 to 49, and 50 years. These age categories were prespecified by the WHI CT. Clinically, these age categories also divide women between those with menopause onset at the population mean age (50 y) and those with younger ages of menopause onset. For this analysis, all women who were randomized to the placebo arms for the HT trial, the Ca/D trial, and the HT þ Ca/D trial were combined into one ''placebo control'' group, creating four treatment levels: control, HT intervention, Ca/D intervention, and HT þ Ca/D intervention. Our primary aim was to determine whether age of menopause altered fracture risk among women treated with HT, Ca/D, or both.
Statistical analyses
Overall baseline demographic characteristics were first summarized by age of menopause group (<40, 40-49, and 50 y). We then determined the number of fractures (hip only and any fracture) in the overall cohort and among the treatment groups (HT, Ca/D, HT þ Ca/D, and control) across the three menopausal ages (<40, 40-49, and 50 y). Cumulative hazard plots using age at fracture as the primary endpoint were calculated. Cox proportional hazard models using age as the time scale were used to assess the impact of age of menopause and treatment on any fracture. First, an unadjusted model with age at menopause and treatment received (control, HT, Ca/D, HT þ Ca/D) as the only covariates was applied to the data. Using this model, the significance of the interaction SULLIVAN ET AL between age at menopause and treatment received was determined. Next, we checked for the presence of significant confounders or effect modifiers to the relationship between age at menopause and fracture using a risk factor modeling approach. 13 Each of the variables listed in Table 1 with <20% missing data were added one at a time to the unadjusted model. To be a confounder, the addition of the variable in the model would have to change the hazard ratios (HRs) for fracture between the different menopause age groups by at least 10%. To be an effect modifier, the two-way interaction between the variable and age at menopause would have to be significant at a P < 0.01 level. All analyses were performed using SAS/STAT software, Version 9.4 of the SAS System for Windows (SAS Institute Inc, Cary, NC).
RESULTS
A total of 47,540 women participated in the WHI HT and/or Ca/D trials. We first excluded 19,912 women with selfreported total hysterectomy (total abdominal hysterectomy) and/or bilateral oophorectomy, or who were enrolled in the E 2 alone trial (indicating prior total abdominal hysterectomy) because of differential estrogen exposure that is known to influence fracture risk. Next, we removed 2,087 women who were missing menopause information and 42 women who were missing data from at least 1 study follow-up visit, resulting in 25,499 women to be included in the analytical sample. The average follow-up time for women in our study cohort was 11.3 years (SD ¼ 4.1 y, range, 0.003-16.8 y). Within this sample, approximately 2% (n ¼ 537 women) reported age of nonsurgical menopause <40 years, compared with 33% (n ¼ 8,449) reporting menopause between age 40 and 49 years and 65% (n ¼ 16,513) reporting menopause at age 50 or later ( Fig. 1 ; Table 1 ).
Demographic characteristics, risk factors for fracture, and treatment group by menopause age group are shown in Table 1 . We observed several differences between the menopause groups. More women with menopause 50 years reported having 3þ children compared with women with menopause <40 years (59% vs 47%, respectively). A larger proportion of women with menopause <40 years were current smokers at baseline compared with women with menopause 50 years (13% vs 7%, respectively). Women with menopause 50 years reported the highest rate of physical activity compared with women with menopause <40 years (17.5þ MET-h/wk, 23% vs 19%, respectively). Women with menopause <40 years had higher rates of past HT use but lower rates of current HT use than women with menopause 50 years (past HT use, 39% vs 15%; current HT use, 17% vs 23%, respectively). In addition, baseline Ca/D intake (combined dietary and supplemental) was higher in menopause 50 years group than the <40 years group Confounding and effect modification were evaluated among the variables listed in Table 1 with <20% missing data (ie, dietary modification trial participation, race/ethnicity, region, education, occupation, body mass index, physical activity, parity, number of falls in the previous 12 mo, smoking status, alcohol use, HT use, history of diabetes, personal history of fracture [overall and at age 55 or later], history of osteoporosis, total baseline vitamin D intake, total baseline calcium intake), as described in the ''Statistical Analyses'' section. Individually, none of the variables listed met the criterion for effect modification, as the minimal P value for any two-way interaction was >0.05 (see Table  S1 , Supplemental Digital Content 1, http://links.lww.com/ MENO/A196, which shows P values for effect modification of all variables). Similarly, none of the variables was deemed a confounding variable, as none of the variables elicited more than a 6% change from the unadjusted hazard ratio (HR) for menopause age (see Table S2 , Supplemental Digital Content 1, http://links. lww.com/MENO/A196, which shows changes in HRs with and without adjustment for each variable in the univariate model). Therefore, we report HRs for fracture calculated using models unadjusted for these variables.
The total number of fractures of any type and the total number of adjudicated hip fractures, overall and by treatment received, and by age of menopause group, are shown in Table 2 . Of note, only 21 women reporting age of menopause <40 years had a hip fracture, thus there was not sufficient statistical power to compare rates of hip fracture across menopause age groups. We therefore focused our analysis on rates of any fracture among study participants. Overall and within each active treatment group, a greater percentage of women with menopause <40 years had a fracture compared with women with older menopause ages. Thus, regardless of the intervention received (ie, HT, Ca/D, HT þ Ca/D), a larger proportion of women with menopause <40 years had a fracture compared with women with older menopause ages (20%, menopause <40 y vs 14%, menopause 40-49 and 50 y) ( Table 2) .
Results from the unadjusted Cox model for any fracture are shown in Table 3 ; the cumulative hazard function by menopause group is shown in Figure 2 . The interaction between age at menopause (<40, 40-49, and 50 y) and treatment received (control, HT, Ca/D, HT þ Ca/D) was not significant (P ¼ 0.452), implying that the effect of menopause age on fracture risk was not meaningfully different between treatment groups. Regardless of treatment group, women with menopause <40 years had a significantly higher risk for any fracture than women with menopause at later ages: the HR for fracture for menopause <40 years versus 50 years was 1.36 (95% CI, 1.11-1.67) and the HR for fracture for menopause <40 years versus 40 to 49 years was 1.30 (95% CI, 1.06-1.60). Of note, HRs calculated after adjusting for all variables in Table 1 14] ). Among the treatment groups, regardless of menopause age, the HR for fracture was higher in women randomized to a placebo than women randomized to Ca/D and women randomized to the combination of HT þ Ca/D (Table 3) . 
MENOPAUSE AGE AND POSTMENOPAUSAL FRACTURE RISK
TABLE 1. Baseline characteristics of uterus-intact women in the WHI intervention trial (HT and Ca/D alone) based on age of menopause

DISCUSSION
In this secondary analysis of the WHI CT, we asked if age of nonsurgical menopause altered the risk for fracture among healthy postmenopausal women who were treated with HT, Ca/D, or both interventions. We found that women with younger ages of menopause (<40 y) had significantly increased risk for any fracture compared to women reporting menopause at older ages (40-49 y or 50 y). This increased fracture risk among women with menopause <40 years remained regardless of study intervention with HT, Ca/D supplementation, or both therapies, all of which have the potential to lessen fracture risk in postmenopausal women. [8] [9] [10] Our findings are in agreement with some, but not all, of previously published investigations of effects of menopause age on fracture risk. For example, both Svejme et al 14 and van Der Voort et al 15 showed that women with early natural menopause had increased risk of fractures in the later postmenopausal years, and several investigators have shown that early age of menopause is an independent risk factor for fractures. 16, 17 On the contrary, Luisetto et al 18 found that chronological age and body mass index were stronger predictors of bone mineral density (BMD) than age of menopause, and further, that after age 60, detrimental effects of early menopause age on BMD were no longer evident. Francucci et al 19 similarly demonstrated that an association between early menopause age and decreased BMD persisted only until age 55 but not beyond, and Ahlborg et al 20 found no influence of menopause age on BMD after age 64.
A potential primary etiology by which earlier menopause age amplifies fracture risk is a longer duration of estrogen deficiency. We, however, showed increased fracture risk even among women reporting menopause <40 years who were treated with EþP HT. Together, these data indicate that age of menopause is a significant independent contributor to fracture risk in postmenopausal women. These findings are congruent with our recent observations of lower BMD and higher fracture risk among uterus-intact postmenopausal women enrolled in the WHI OS who reported menopause <40 years compared with women in the same study reporting menopause between ages 40 to 49 years and 50 years. In the WHI OS, there was, however, no treatment intervention, thus any potential interaction between menopause age and boneprotective treatments could not be ascertained.
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SULLIVAN ET AL
In our present analysis, we found that overall, control women had higher risk of fracture than women in the EþP and/or Ca/D treatment groups, that is, the effect of treatment as a predictor of fracture was highly significant (P ¼ 0.004) ( Table 3 ). In considering the effect of treatment relative to the relationship between menopause age and fracture, we, however, found no evidence that treatment with EþP and/or Ca/D significantly altered the relationship between age at menopause and fracture risk, that is, treatment did not change the effect of menopause age on fracture risk. This suggests that early age of menopause is a potent risk factor for fracture in postmenopausal women and should be taken into account when assessing overall fracture risk in this population. It is possible that earlier initiation of treatment with Ca/D and/or HT, longer duration of treatment, or longer duration of followup would show an interaction between menopause age and these bone-protecting treatments. It is also possible that among women treated with EþP, antiestrogenic effects of the progestin component counteracted any benefits that may have been attributable to the estrogen component of HT on bone. Our data, however, indicate that early menopause age may be a predominant risk factor predicting fracture risk after menopause despite commonly used therapeutic interventions.
We did not find differences in the percentages of women with fractures (Table 2) or the risk for fracture (Table 3 ; Fig. 2 ) between women with menopause age 40 to 49 years versus 50 years. This was perhaps due to small numbers of fractures within each subgroup. With a larger fracture incidence in the overall cohort, smaller differences in fracture risk that occur on the continuum of menopause age may have become evident. Another contributing factor may be that this time difference in menopause onset-the fifth rather than the sixth decade of life-does not allow sufficient time to result in observable changes in fracture risk. Finally, a longer time of follow-up may have demonstrated differences in fracture risk that become more pronounced with advancing chronological age.
In our comparison of demographic characteristics among women in the three menopause age groups, we found several differences, including parity, smoking status, current and past HT use, activity level, and total daily Ca/D intake, all of which could have altered fracture risk between the groups. None of these variables, however, proved to be statistical confounders or effect modifiers in our model analyzing HR for fracture, suggesting the differences we found were due to differences in menopause age rather than differences in other risk factors or demographic factors. Indeed, HRs for fracture were similar in our model with and without adjustment for these variables, indicating age of menopause was the primary predictor of fracture risk.
The number of women reporting menopause <40 years who reported a hip fracture was very small, precluding an analysis of the HR for adjudicated hip fracture among the menopause age groups in the WHI CT. That said, in the HT and Ca/D intervention groups, women with menopause <40 years exhibited a higher prevalence of hip fracture than women in the older menopause age groups (6% vs 3%; Table 2 ). Further research with larger numbers of postmenopausal women reporting younger menopause age and hip fracture is needed to confirm whether the differences we observed in hip fracture rates across menopause age groups are statistically or clinically significant.
We conducted our primary analysis using data on rates of any fracture among the WHI CT cohort, which limits the specificity of our conclusions. ''Any fracture'' is used to describe the composite of fractures at the hip/pelvis/upper leg, lower leg/ankle/knee, foot, upper arm/shoulder/elbow, lower arm/wrist/hand, and spine/tailbone. When looking at specific fracture types among our cohort, we found that the absolute numbers for each fracture type were too small within each menopause age group to determine if menopause age altered risk for a particular fracture type, such as wrist or hip fracture. Nevertheless, the distribution of fracture types across the menopause age groups was similar, thus we performed our analysis on the composite of ''any fracture.'' We were also unable to assess causality of fractures (ie, traumatic or atraumatic/osteoporotic), therefore we can only speculate that the increase in fracture risk we observed was due to an increase in the prevalence of postmenopausal loss of BMD. In that regard, we had limited data on BMD as assessed by dual-energy x-ray absorptiometry among women in this cohort for meaningful comparisons across groups; however, in our previous report examining the effect of menopause age on fracture risk in naturally postmenopausal women in the WHI OS, 11 we found that earlier menopause age not only increased fracture risk, but was also associated with significant decreases in BMD.
Strengths of this study include a large cohort of wellcharacterized, naturally postmenopausal women with information on many osteoporotic risk factors (including past and current use of calcium, vitamin D, and HT and major comorbidities), menopausal age, and detailed fracture data. Limitations include its retrospective design; overall small numbers of fractures, particularly among women with age of menopause <40 years; lack of information on serum 25-hydroxyvitamin D levels; lack of physician confirmation of menopause onset, and our inability to control for all osteoporotic risk factors in all participants (eg, data on family history of fracture were available for only a small subset of women). Given our study's strengths and despite its limitations, our data present a clear signal of an increase in overall fracture risk seen in women who experience younger ages of natural menopause.
CONCLUSIONS
This secondary analysis of over 25,000 healthy postmenopausal women suggests that younger menopause age is a strong predictor of increased fracture occurrence in the postmenopausal years and that treatment with HT, Ca/D, or the combination does not influence this association.
